Overview
Phase 2 study of RPT193 in adults with atopic dermatitis
Description
Randomized, placebo-controlled Phase 2 study of RPT193 in adults with moderate-to-severe atopic dermatitis
Eligibility
Inclusion Criteria:
- Clinically confirmed diagnosis of active atopic dermatitis (AD), according to the revised Hanifin and Rajka criteria
- 12-month history of AD and had no significant flares in AD for at least 4 weeks before screening
- inadequate response to a ≥1 month treatment with topical medications
- Atopic dermatitis covering ≥10% of the body surface area
- EASI score ≥16
- Validated Investigator Global Assessment (VIGA) ≥3
- Use of emollient(s) at least 2x daily for 1 week prior to baseline
- Negative coronavirus disease (COVID)-19 results at screening
Exclusion Criteria:
- Uncontrolled moderate-to-severe asthma
- Uncontrolled diabetes
- Stage III or IV cardiac failure
- Severe renal condition
- Major surgery within 8 weeks of screening
- Immunodeficiency and/or receipt of immunosuppressive drugs within 4 weeks of baseline
- Use of systemic Janus kinase (JAK) inhibitor within 8 weeks of baseline
- Received live or live-attenuated vaccine within 4 weeks of baseline
- Prior receipt of RPT193